Gland Pharma Limited has issued a postal ballot notice seeking shareholder approval for the reappointment of Ms. Naina Lal Kidwai as an Independent Director. The company's Board of Directors had earlier approved her reappointment for a second consecutive term during their meeting held on April 09, 2026.

Regulatory Compliance and Publication

In compliance with Regulation 47 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, the company published newspaper advertisements in English and regional Telugu newspapers regarding the dispatch of the postal ballot notice. The regulatory filing was submitted to stock exchanges on April 14, 2026, by Company Secretary Sampath Kumar Pallerlamudi.

Postal Ballot Process and Timeline

The company has engaged MUFG Intime India Private Limited as the registrar and transfer agent to facilitate the e-voting process. The postal ballot notice was dispatched to shareholders on April 13, 2026, with detailed voting procedures and timelines:

Reappointment Details and Remuneration Structure

The special resolution seeks approval for Ms. Kidwai's reappointment as Independent Director for a second term of five consecutive years, effective from May 17, 2026, to May 16, 2031. The appointment includes a commission-based remuneration structure:

E-voting Process and Shareholder Communication

The postal ballot process complies with Section 110 of the Companies Act, 2013, and various MCA circulars. The company has sent the notice electronically to shareholders whose email addresses are registered with depositories or the company. Physical copies are not being distributed in accordance with MCA circulars.

The notice is available on the company's website and will also be accessible through stock exchange websites. Shareholders holding shares as of the cut-off date will be eligible to vote through the remote e-voting system only.

Director Profile and Board Contribution

Ms. Naina Lal Kidwai brings extensive experience to Gland Pharma's board, currently serving as Chairman of Rothschild & Co India and holding various advisory positions. Her qualifications include an MBA from Harvard Business School and recognition through the Padma Shri award for contributions to trade and industry.

During her current tenure from May 17, 2021, she has served as Chairperson of the Risk Management Committee and attended all six board meetings held. Her expertise spans banking, finance, sustainability, and corporate governance, making her a valuable contributor to the company's strategic direction.

The board believes her reappointment will continue to benefit the company through her extensive background in finance, strategy, management, and governance, particularly given her active participation in challenging business decisions during her current tenure.

Gland Pharma Limited has fulfilled its quarterly regulatory compliance by submitting a certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026.

Regulatory Compliance Details

The pharmaceutical company submitted the mandatory certificate to both BSE Limited and National Stock Exchange of India Limited on April 13, 2026. The submission was made by Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer, ensuring adherence to regulatory timelines.

Certificate Confirmation

The confirmation certificate was issued by MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, which serves as the company's Registrar and Share Transfer Agent. Ashok Shetty, Sr. Vice President – Corporate Registry at MUFG Intime, signed the certificate confirming compliance with regulatory requirements.

Key Regulatory Statement

The certificate specifically confirms that no requests for dematerialization or rematerialization of equity shares were received during the quarter ended March 31, 2026. This confirmation is mandated under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, which requires periodic reporting of share transfer activities.

Corporate Information

Gland Pharma Limited maintains its registered office at Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads, D.P. Pally, Dundigal, in Medchal-Malkajgiri District, Hyderabad. The company's corporate office is located at Plot No. 11 & 84, TSIIC Phase IV, Pashamylaram, Patancheru, Sangareddy District, Hyderabad. This quarterly submission demonstrates the company's commitment to maintaining transparent regulatory compliance and proper corporate governance practices in accordance with SEBI guidelines.